Dr Reddy's Clarifies Thailand Approval for Gonorrhea Drug

Dr Reddy's Laboratories Ltd has issued a clarification regarding a news item about its gonorrhea drug, NUZOLVENCE® (zoliflodacin), receiving approval from the Thai FDA. The company confirmed the news is correct, stating it pertains to a joint press release with GARDP made on July 27, 2026. This approval follows the US authorization six months prior. Dr Reddy's clarified that this event does not constitute a material event requiring disclosure under SEBI Listing Regulations, emphasizing their commitment to timely disclosures of material information.